On July 9, 2026, UK pharmaceutical group AstraZeneca and U.S.-based Ionis Pharmaceuticals announced that the global Phase III CARDIO-TTRansform trial of Wainua in transthyretin-mediated amyloid cardiomyopathy, or ATTR-CM, had failed to meet its primary efficacy endpoint. The study was designed to evaluate whether the treatment could reduce cardiovascular mortality and recurrent cardiovascular events over a period of up to 140 weeks. However, the results did not show a statistically significant benefit compared with standard care.
The market reacted sharply to the news. AstraZeneca’s shares dropped nearly 10% at one point during trading, wiping out approximately $27 billion in market value. The scale of the decline reflected investor expectations that Wainua could become a major growth driver in the company’s cardiovascular portfolio.
The setback drew particular attention because Wainua was not a minor or early-stage asset. The RNA-targeting therapy works by lowering transthyretin protein levels and has already been approved for the treatment of ATTR polyneuropathy. AstraZeneca had been aiming to expand its use into ATTR-CM, a larger and more commercially attractive patient population, as part of its broader strategy to strengthen its cardiovascular, renal and metabolism business.
Competition in the ATTR-CM space is already intense. Pfizer’s Vyndaqel and Vyndamax, BridgeBio’s Attruby, and Alnylam’s Amvuttra all target the disease through different mechanisms, including protein stabilization and gene silencing. Without clear evidence that Wainua can improve major clinical outcomes, physicians and payers may be reluctant to switch patients from established therapies. Following the trial results, shares of several competing companies rose, indicating a rapid reassessment of competitive positioning in the market.
The outcome also highlights a broader lesson in drug development: improvements in biomarkers do not necessarily translate into meaningful clinical benefits. Although Wainua has demonstrated the ability to significantly reduce transthyretin protein levels, regulators and clinicians ultimately focus on outcomes such as survival, hospitalization rates and cardiovascular events. Large-scale cardiovascular trials are complex and influenced by multiple factors, including background therapies, making success on hard endpoints particularly challenging.
While the $27 billion decline in market value may partly reflect an overreaction, given AstraZeneca’s diversified pipeline in oncology and chronic diseases, the failed trial still represents a meaningful setback. It removes a key pillar supporting the company’s long-term growth expectations and forces management to reassess the future role of Wainua in treating cardiomyopathy.
